Discriminating Inflammatory Radiation-Related Changes From Early Recurrence in Patients With Glioblastomas: A Preliminary Analysis of 68 Ga-PSMA-11 PET/CT Compared With 18 F-FDOPA PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
medline:
3
7
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
Using morphological and functional imaging to discriminate recurrence from postradiation-related modifications in patients with glioblastomas remains challenging. This pilot study aimed to assess the feasibility of using 68 Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT compared with 18 F-FDOPA PET/CT to detect early recurrence. Nine patients followed up for glioblastomas who received MRI during 12 months of follow-up were referred for both 68 Ga-PSMA-11 and 18 F-FDOPA PET/CT. The SUV max , lesion-to-striatum ratio, lesion-to-normal parenchyma ratio, and lesion-to-salivary gland ratio were calculated. Good correlation between 18 F-FDOPA and 68 Ga-PSMA PET/CT findings was seen in 5 patients. In 4 patients, the findings of both examinations were consistent with recurrence but were better visualized with the PSMA PET/CT. Examinations of the fifth patient were suggestive of postradiation-related changes and were better analyzed with the PSMA PET/CT, which displayed relatively low uptake compared with DOPA PET/CT. Conversely, 4 patients showed conflicting results: recurrence was not detected on the PSMA PET/CT because of previously introduced bevacizumab treatment; in another patient, both examinations were consistent with recurrence, but there was an uptake mismatch at the suspected lesion sites, and 2 patients presented with inconsistent findings. Despite a few discrepancies, this study highlights the potential role of 68 Ga-PSMA-11 PET/CT for discriminating postradiation inflammation from recurrence. 68 Ga-PSMA-11 PET/CT has an excellent lesion-to-background ratio, and false-positive and false-negative results could be minimized through implementing certain protocols before performing the examination. More powerful prospective studies are required to validate our results.
Identifiants
pubmed: 37276534
doi: 10.1097/RLU.0000000000004716
pii: 00003072-202308000-00001
doi:
Substances chimiques
Gallium Isotopes
0
PSMA-11
0
Gallium-68
98B30EPP5S
Gallium Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-666Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Osborn AG, Louis DN, Poussaint TY, et al. The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol . 2022;43:928–937.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol . 2021;23:1231–1251.
Hustinx R, Pourdehnad M, Kaschten B, et al. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am . 2005;43:35–47.
Eisele SC, Wen PY, Lee EQ. Assessment of brain tumor response: RANO and its offspring. Curr Treat Options Oncol . 2016;17:35.
Albert NL, Weller M, Suchorska B, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. NEUONC . 2016;18:1199–1208.
Chen W, Silverman DHS, Delaloye S, et al. 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med . 2006;47:904–911.
Calabria F, Cascini GL. Current status of 18 F-DOPA PET imaging in the detection of brain tumor recurrence. Hell J Nucl Med . 2015;18:152–156.
Herrmann K, Czernin J, Cloughesy T, et al. Comparison of visual and semiquantitative analysis of 18 F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol . 2014;16:603–609.
Karunanithi S, Sharma P, Kumar A, et al. 18 F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging . 2013;40:1025–1035.
Jena A, Taneja S, Khan AA, et al. Recurrent glioma: does qualitative simultaneous 18 F-DOPA PET/mp-MRI improve diagnostic workup? An initial experience. Clin Nucl Med . 2021;46:703–709.
Sharma A, McConathy J. Overview of PET tracers for brain tumor imaging. PET Clin . 2013;8:129–146.
Schwenck J, Tabatabai G, Skardelly M, et al. In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging . 2015;42:170–171.
Salas Fragomeni RA, Menke JR, Holdhoff M, et al. Prostate-specific membrane antigen–targeted imaging with [ 18 F]DCFPyL in high-grade gliomas. Clin Nucl Med . 2017;42:e433–e435.
Wernicke AG, Edgar MA, Lavi E, et al. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med . 2011;135:1486–1489.
Nomura N, Pastorino S, Jiang P, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int . 2014;14:26.
Sasikumar A, Joy A, Pillai MRA, et al. Diagnostic value of 68 Ga PSMA-11 PET/CT imaging of brain tumors—preliminary analysis. Clin Nucl Med . 2017;42:e41–e48.
Lizarraga KJ, Allen-Auerbach M, Czernin J, et al. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med . 2014;55:30–36.
Reverchon J, Khayi F, Roger M, et al. Optimization of the radiosynthesis of [ 68 Ga]Ga-PSMA-11 using a Trasis MiniAiO synthesizer: do we need to heat and purify? Nucl Med Commun . 2020;41:977–985.
Ledezma CJ, Chen W, Sai V, et al. 18 F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol . 2009;71:242–248.
Zaragori T, Ginet M, Marie PY, et al. Use of static and dynamic [ 18 F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression. EJNMMI Res . 2020;10:56.
Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging . 2014;41:11–20.
Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging . 2015;42:197–209.
Afshar-Oromieh A, Holland-Letz T, Giesel FL, et al. Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging . 2017;44:1258–1268.
Fendler WP, Eiber M, Beheshti M, et al. 68 Ga-PSMA PET/CT: Joint EANM and SNMMI Procedure Guideline for Prostate Cancer Imaging: Version 1.0. Eur J Nucl Med Mol Imaging . 2017;44:1014–1024.
Hope TA, Aggarwal R, Chee B, et al. Impact of 68 Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med . 2017;58:1956–1961.
Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res . 1997;3:81–85.
Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res . 1999;5:2674–2681.
Chang SS, Reuter VE, Heston WD, et al. Five different anti–prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res . 1999;59:3192–3198.
Mahzouni P, Shavakhi M. Prostate-specific membrane antigen expression in neovasculature of glioblastoma multiforme. Adv Biomed Res . 2019;8:18.
Holzgreve A, Biczok A, Ruf VC, et al. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front Oncol . 2021;11:646387.
Salas Fragomeni RA, Pienta KJ, Pomper MG, et al. Uptake of prostate-specific membrane antigen–targeted 18 F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas. Clin Nucl Med . 2018;43:e419–e421.
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)–targeted PET imaging. Eur J Nucl Med Mol Imaging . 2017;44:2117–2136.
Hofman MS, Hicks RJ, Maurer T, et al. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics . 2018;38:200–217.
Kunikowska J, Bartosz K, Leszek K. Glioblastoma multiforme: another potential application for 68 Ga-PSMA PET/CT as a guide for targeted therapy. Eur J Nucl Med Mol Imaging . 2018;45:886–887.
Pilati E, Nicolotti DG, Ceci F, et al. 68 Ga–prostate-specific membrane antigen 11 PET/CT detects residual glioblastoma after radical surgery in a patient with synchronous recurrent prostate cancer: a case report. Clin Nucl Med . 2020;45:e151–e153.
Jiang JY, Kang C, Bui P, et al. Incidental prostate-specific membrane antigen–avid glioblastoma detected on 68 Ga–prostate-specific membrane antigen PET/CT. Radiol Case Rep . 2022;17:2023–2025.
Muoio B, Albano D, Dondi F, et al. Diagnostic accuracy of PET/CT or PET/MRI using PSMA-targeting radiopharmaceuticals in high-grade gliomas: a systematic review and a bivariate meta-analysis. Diagnostics (Basel) . 2022;12:1665.
Verma P, Malhotra G, Goel A, et al. Differential uptake of 68 Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients. Clin Nucl Med . 2019;44:e318–e322.
Sasikumar A, Kashyap R, Joy A, et al. Utility of 68 Ga-PSMA-11 PET/CT in imaging of glioma—a pilot study. Clin Nucl Med . 2018;43:e304–e309.
Kunikowska J, Kuliński R, Muylle K, et al. 68 Ga–prostate-specific membrane Antigen-11 PET/CT: a new imaging option for recurrent glioblastoma multiforme? Clin Nucl Med . 2020;45:11–18.
Youland RS, Kitange GJ, Peterson TE, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol . 2013;111:11–18.
Dadone-Montaudié B, Ambrosetti D, Dufour M, et al. [ 18 F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One . 2017;12:e0184625.
Schiepers C, Chen W, Cloughesy T, et al. 18 F-FDOPA kinetics in brain tumors. J Nucl Med . 2007;48:1651–1661.
Traub-Weidinger T, Poetsch N, Woehrer A, et al. PSMA expression in 122 treatment naive glioma patients related to tumor metabolism in 11 C-methionine PET and survival. J Pers Med . 2021;11:624.
Lindemann M, Oteiza A, Martin-Armas M, et al. Glioblastoma PET/MRI: kinetic investigation of [ 18 F]rhPSMA-7.3, [ 18 F]FET and [ 18 F]fluciclovine in an orthotopic mouse model of cancer. Eur J Nucl Med Mol Imaging . 2022.
Moreau A, Marie E, Bonneville-Levard A, et al. Skull vault hemangioma mimicking neoplastic lesion on [ 68 Ga]Ga-PSMA-11 PET/CT in a patient with glioblastoma: a case report. Radiol Case Rep . 2020;15:2598–2601.
Sala Q, Metellus P, Taieb D, et al. 18 F-DOPA, a clinically available PET tracer to study brain inflammation? Clin Nucl Med . 2014;39:e283–e285.
Calabria FF, Chiaravalloti A, Calabria EN, et al. 18 F-DOPA PET/CT and MRI findings in a patient with multiple meningiomas. Clin Nucl Med . 2016;41:636–637.
Gupta M, Choudhury PS, Gairola M, et al. Pseudoprogression on 68 Ga–prostate-specific membrane antigen-11 PET/CT in a treated glioblastoma. Clin Nucl Med . 2020;45:621–622.
Gordon IO, Tretiakova MS, Noffsinger AE, et al. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol . 2008;21:1421–1427.
Moreau A, Cruel T, Giraudet AL, et al. Incidental finding of hibernoma in prostate-specific membrane antigen PET/CT. Clin Nucl Med . 2021;46:e469–e470.
Moreau A, Pretet V, Paquet E, et al. Intense diffuse lung uptake due to interstitial pneumopathy related to polyangiitis granulomata in 68 Ga-PSMA-11 PET/CT. Clin Nucl Med . 2023;48:261–263.
Kumar A, ArunRaj ST, Bhullar K, et al. Ga-68 PSMA PET/CT in recurrent high-grade gliomas: evaluating PSMA expression in vivo. Neuroradiology . 2022;64:969–979.
Uijen MJM, Derks YHW, Merkx RIJ, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging . 2021;48:4350–4368.
Marafi F, Sasikumar A, Fathallah W, et al. 18 F-PSMA 1007 brain PET/CT imaging in glioma recurrence. Clin Nucl Med . 2020;45:e61–e62.
Kirchner MA, Holzgreve A, Brendel M, et al. PSMA PET imaging in glioblastoma: a preclinical evaluation and theranostic outlook. Front Oncol . 2021;11:774017.
Kunikowska J, Charzyńska I, Kuliński R, et al. Tumor uptake in glioblastoma multiforme after IV injection of [ 177 Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging . 2020;47:1605–1606.
Kumar A, Ballal S, Yadav MP, et al. 177 Lu-/ 68 Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept. Clin Nucl Med . 2020;45:e512–e513.
More S, Naiker T, Jacobs N, et al. Short-interval, low-dose [ 177 Lu]Lu–prostate-specific membrane antigen in the treatment of refractory glioblastoma. Clin Nucl Med . 2023;48:e217–e218.